Literature DB >> 2433347

Kinetics and specificity of T and B cell responses in relapsing experimental allergic encephalomyelitis.

L L Perry, M E Barzaga.   

Abstract

T and B cell responses to myelin basic protein (MBP) and its relevant peptide fragments were examined throughout the course of MBP-induced relapsing experimental allergic encephalomyelitis (REAE) in (SJL X PL)F1 mice. T cell reactivity, measured by the antigen-driven proliferation of lymph node T cells in vitro, was directed predominantly against the encephalitogenic MBP-P2 peptide (amino acids 1 to 37) at all stages of disease. Levels of responsiveness did not correlate with disease expression, but declined over time to a relapse level that was four- to sixfold lower than that observed during peak acute stage reactivity. Relapse responses were further distinguished by the detection of host I-E restrictions on Lyt-1+ T cell recognition of P2, P2 recognition by acute-stage T cells occurring solely in the context of host I-A molecules. These data imply an increase in the heterogeneity of relapse T cell responses to MBP to include clones restricted by additional class II glycoproteins. A role for additional CNS autoantigens in the stimulation of relapse T cells is also considered. Serum antibody responses to MBP or the P2 fragment fluctuated randomly throughout R-EAE when total antibody activity (IgM plus IgG) was measured. However, analysis of individual isotypes of IgG immunoglobulins revealed an apparent correlation between peak antigen-binding activity and disease expression which may reflect either an effector or regulatory role for humoral immunity in recurrent EAE. Patterns of early antibody reactivity also distinguished F1 mice that developed or failed to develop disease signs after immunization, the latter exhibiting a consistent drop in antigen-binding activity 4 to 5 days before the usual onset of acute-stage paralysis. The results are considered with regard to possible mechanisms of chronic disease regulation in an environment of functional T cell suppression.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2433347

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Mechanisms of immune-mediated demyelinating disease of the central nervous system.

Authors:  D Baker; A N Davison
Journal:  Neurochem Res       Date:  1991-09       Impact factor: 3.996

2.  Role of platelet activating factor in the pathogenesis of active and passive models of experimental allergic encephalomyelitis in the rat.

Authors:  S Desai; R Barton
Journal:  Agents Actions       Date:  1990-08

3.  Contrasting effects from a single major histocompatibility complex class II molecule (H-2E) in recovery from Friend virus leukemia.

Authors:  L L Perry; M Miyazawa; K Hasenkrug; K Wehrly; C S David; B Chesebro
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

4.  Evidence for multiple mechanisms of polyclonal T cell activation in murine lupus.

Authors:  R R Singh; B H Hahn; B P Tsao; F M Ebling
Journal:  J Clin Invest       Date:  1998-11-15       Impact factor: 14.808

5.  T cell sensitization to proteolipid protein in myelin basic protein-induced relapsing experimental allergic encephalomyelitis.

Authors:  L L Perry; E Barzaga-Gilbert; J L Trotter
Journal:  J Neuroimmunol       Date:  1991-07       Impact factor: 3.478

Review 6.  Epitope spreading.

Authors:  C J Vanderlugt; S D Miller
Journal:  Curr Opin Immunol       Date:  1996-12       Impact factor: 7.486

7.  Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis.

Authors:  B L McRae; C L Vanderlugt; M C Dal Canto; S D Miller
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

8.  Encephalitogenicity of myelin basic protein exon-2 peptide in mice.

Authors:  R B Fritz; M L Zhao
Journal:  J Neuroimmunol       Date:  1994-04       Impact factor: 3.478

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.